CA 19-9 and Lewis Antigens in Pancreatic Cancer Reply

被引：0
|
作者：
Berger, Adam C. [1 ]
Hoffman, John P. [2 ]
Winter, Kathryn [3 ]
Regine, William [4 ]
Safran, Howard [5 ]
Abrams, Ross [6 ]
Willet, Christopher [7 ]
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[3] Radiat Therapy Oncol Grp, Philadelphia, PA USA
[4] Univ Maryland, Baltimore, MD 21201 USA
[5] Brown Univ, Providence, RI 02912 USA
[6] Rush Univ, Chicago, IL 60612 USA
[7] Duke Univ, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
10.1200/JCO.2009.21.9600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2573 / 2573
页数：1
相关论文
共 50 条
  • [21] Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions
    Cwik, Grzegorz
    Wallner, Grzegorz
    Skoczylas, Tomasz
    Ciechanski, Aleksander
    Zinkiewicz, Krzysztof
    ARCHIVES OF SURGERY, 2006, 141 (10) : 968 - 973
  • [22] CA 19-9 in the differential diagnosis of pancreatic lesions
    Stintzing, S.
    Herold, C.
    Hahn, E. G.
    Boxberger, F.
    INTERNIST, 2008, 49 (02): : 225 - 227
  • [23] Serum levels of CA 19-9 in patients with pancreatic cancer and liver cirrhosis
    Kadayifci, A
    Simsek, H
    Usalan, C
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1995, 14 (04) : 435 - 437
  • [24] Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review
    Ballehaninna U.K.
    Chamberlain R.S.
    Indian Journal of Surgical Oncology, 2011, 2 (2) : 88 - 100
  • [25] CA 19-9 as a predictor of cancer in the presence of pancreatic stricture demonstrated by ERCP
    Kirk, K
    Kasmin, FE
    Cohen, SA
    Siegel, JH
    GASTROENTEROLOGY, 2001, 120 (05) : A609 - A609
  • [26] EFFICACY OF CA 19-9, TPA AND CEA ASSAYS IN PANCREATIC-CANCER
    ANDRIULLI, A
    GINDRO, T
    PIANTINO, P
    MASOERO, G
    CAVALLINI, G
    FARINI, R
    PIAZZI, L
    DOBRILLA, G
    NACCARATO, R
    SCURO, LA
    DIGESTION, 1983, 28 (01) : 9 - 10
  • [27] Prognostic value of CA 19-9 in patients with pancreatic cancer treated with Gemcitabine
    Halm, U
    Schuhmann, T
    Keim, V
    Moessner, J
    GASTROENTEROLOGY, 1999, 116 (04) : A1129 - A1129
  • [28] CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients
    Santucci, Nicolas
    Facy, Olivier
    Ortega-Deballon, Pablo
    Lequeu, Jean-Baptiste
    Rat, Paul
    Rat, Patrick
    PANCREATOLOGY, 2018, 18 (06) : 666 - 670
  • [29] CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer
    Karachristos, A
    Scarmeas, N
    Hoffman, JP
    JOURNAL OF GASTROINTESTINAL SURGERY, 2005, 9 (09) : 1286 - 1292
  • [30] Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer
    Ohara, K
    Tatsuzaki, H
    Molotkova, NG
    Oda, T
    Yuzawa, K
    Saida, Y
    Matsuzaki, Y
    Shimizu, W
    Todoroki, T
    Fukao, K
    Tanaka, N
    Itai, Y
    HEPATO-GASTROENTEROLOGY, 2001, 48 (39) : 859 - 863
12345